ARX788 Meets PFS End Point in HER2+ Metastatic Breast Cancer
OncLive,
Daniel O’Connor The antibody-drug conjugate (ADC) ARX788 was found to significantly improve progression-free survival (PFS…
Daniel O’Connor The antibody-drug conjugate (ADC) ARX788 was found to significantly improve progression-free survival (PFS…
In 2013, ado-trastuzumab emtansine (T-DM1; Kadcyla) gained FDA approval for the treatment of patients with HER2-positive…
Recent therapeutic advances in HER2-positive metastatic breast cancer (MBC) have begun to reshape the treatment landscape for…
Recent therapeutic advances in HER2-positive metastatic breast cancer (MBC) have begun to reshape the treatment landscape for…
The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a…
The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a…
Fast track designation was granted to the anti-HER2 antibody-drug conjugate ARX788 as monotherapy for the treatment of patients…